Latest:
FDA Approves New Neuromyelitis Optica Spectrum Disorder Treatment
Satralizumab represents only the second targeted treatment for NMOSD and the first cleared for at-home administration.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.